These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

192 related items for PubMed ID: 14732933

  • 1. Immunomodulation by the copolymer glatiramer acetate.
    Arnon R, Sela M.
    J Mol Recognit; 2003; 16(6):412-21. PubMed ID: 14732933
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Oral glatiramer acetate in experimental autoimmune encephalomyelitis: clinical and immunological studies.
    Teitelbaum D, Aharoni R, Klinger E, Kreitman R, Raymond E, Malley A, Shofti R, Sela M, Arnon R.
    Ann N Y Acad Sci; 2004 Dec; 1029():239-49. PubMed ID: 15681762
    [Abstract] [Full Text] [Related]

  • 4. Glatiramer acetate: mechanisms of action in multiple sclerosis.
    Ziemssen T, Schrempf W.
    Int Rev Neurobiol; 2007 Dec; 79():537-70. PubMed ID: 17531858
    [Abstract] [Full Text] [Related]

  • 5. Copolymer-1.
    Comi G, Moiola L.
    Baillieres Clin Neurol; 1997 Oct; 6(3):495-509. PubMed ID: 10101586
    [Abstract] [Full Text] [Related]

  • 6. Glatiramer acetate: mechanisms of action in multiple sclerosis.
    Schrempf W, Ziemssen T.
    Autoimmun Rev; 2007 Aug; 6(7):469-75. PubMed ID: 17643935
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Do Th2 cells mediate the effects of glatiramer acetate in experimental autoimmune encephalomyelitis?
    Jee Y, Liu R, Bai XF, Campagnolo DI, Shi FD, Vollmer TL.
    Int Immunol; 2006 Apr; 18(4):537-44. PubMed ID: 16481342
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Immunomodulation neuroprotection and remyelination - the fundamental therapeutic effects of glatiramer acetate: a critical review.
    Aharoni R.
    J Autoimmun; 2014 Nov; 54():81-92. PubMed ID: 24934599
    [Abstract] [Full Text] [Related]

  • 13. Short-term combination of glatiramer acetate with i.v. steroid treatment preceding treatment with GA alone assessed by MRI-disease activity in patients with relapsing-remitting multiple sclerosis.
    De Stefano N, Filippi M, Hawkins C, 9011 study group.
    J Neurol Sci; 2008 Mar 15; 266(1-2):44-50. PubMed ID: 17897678
    [Abstract] [Full Text] [Related]

  • 14. Glatiramer acetate treatment does not modify the clinical course of (NZB x BXSB)F1 lupus murine model.
    Borel P, Benkhoucha M, Weber MS, Zamvil SS, Santiago-Raber ML, Lalive PH.
    Int Immunol; 2008 Oct 15; 20(10):1313-9. PubMed ID: 18687587
    [Abstract] [Full Text] [Related]

  • 15. Glatiramer acetate for treatment of relapsing-remitting multiple sclerosis.
    Johnson KP.
    Expert Rev Neurother; 2012 Apr 15; 12(4):371-84. PubMed ID: 22449210
    [Abstract] [Full Text] [Related]

  • 16. Suppression of experimental allergic encephalomyelitis by COP1--relevance to multiple sclerosis.
    Arnon R, Teitelbaum D, Sela M.
    Isr J Med Sci; 1989 Dec 15; 25(12):686-9. PubMed ID: 2533187
    [Abstract] [Full Text] [Related]

  • 17. [Newer disease--modifying drugs: glatiramer acetate and mitoxantrone].
    Kohriyama T, Higaki M, Matsumoto M.
    Nihon Rinsho; 2003 Aug 15; 61(8):1381-7. PubMed ID: 12962027
    [Abstract] [Full Text] [Related]

  • 18. Cop 1 as a candidate drug for multiple sclerosis.
    Teitelbaum D, Arnon R, Sela M.
    J Neural Transm Suppl; 1997 Aug 15; 49():85-91. PubMed ID: 9266417
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.